Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Danielle Haber

    TitleAssociate Physician
    SchoolUniversity of California, San Diego
    DepartmentPsychiatry
    Address9500 Gilman Drive #0980
    CA La Jolla 92093
    Phone858-534-9534
    vCardDownload vCard

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Jiang X, Wong KHK, Khankhel AH, Zeinali M, Reategui E, Phillips MJ, Luo X, Aceto N, Fachin F, Hoang AN, Kim W, Jensen AE, Sequist LV, Maheswaran S, Haber D, Stott SL, Toner M. Microfluidic isolation of platelet-covered circulating tumor cells. Lab Chip. 2017 Sep 21. PMID: 28932842.
        View in: PubMed
      2. Fachin F, Spuhler P, Martel-Foley JM, Edd JF, Barber TA, Walsh J, Karabacak M, Pai V, Yu M, Smith K, Hwang H, Yang J, Shah S, Yarmush R, Sequist LV, Stott SL, Maheswaran S, Haber D, Kapur R, Toner M. Monolithic Chip for High-throughput Blood Cell Depletion to Sort Rare Circulating Tumor Cells. Sci Rep. 2017 Sep 07; 7(1):10936. PMID: 28883519.
        View in: PubMed
      3. Franses JW, Basar O, Kadayifci A, Yuksel O, Choz M, Kulkarni AS, Tai E, Vo KD, Arora KS, Desai N, Licausi JA, Toner M, Maheswaran S, Haber D, Ryan DP, Brugge WR, Ting DT. Improved Detection of Circulating Epithelial Cells in Patients with Intraductal Papillary Mucinous Neoplasms. Oncologist. 2017 Aug 31. PMID: 28860411.
        View in: PubMed
      4. Polak P, Kim J, Braunstein LZ, Karlic R, Haradhavala NJ, Tiao G, Rosebrock D, Livitz D, Kübler K, Mouw KW, Kamburov A, Maruvka YE, Leshchiner I, Lander ES, Golub TR, Zick A, Orthwein A, Lawrence MS, Batra RN, Caldas C, Haber D, Laird PW, Shen H, Ellisen LW, D'Andrea AD, Chanock SJ, Foulkes WD, Getz G. A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. Nat Genet. 2017 Aug 21. PMID: 28825726.
        View in: PubMed
      5. Sandlin RD, Wong KHK, Boneschansker L, Carey TR, Miller KL, Rose G, Haber D, Maheswaran S, Irimia D, Stott SL, Toner M. Preservative solution that stabilizes erythrocyte morphology and leukocyte viability under ambient conditions. Sci Rep. 2017 Jul 18; 7(1):5658. PMID: 28720788.
        View in: PubMed
      6. Viswanathan VS, Ryan MJ, Dhruv HD, Gill S, Eichhoff OM, Seashore-Ludlow B, Kaffenberger SD, Eaton JK, Shimada K, Aguirre AJ, Viswanathan SR, Chattopadhyay S, Tamayo P, Yang WS, Rees MG, Chen S, Boskovic ZV, Javaid S, Huang C, Wu X, Tseng YY, Roider EM, Gao D, Cleary JM, Wolpin BM, Mesirov JP, Haber D, Engelman JA, Boehm JS, Kotz JD, Hon CS, Chen Y, Hahn WC, Levesque MP, Doench JG, Berens ME, Shamji AF, Clemons PA, Stockwell BR, Schreiber SL. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature. 2017 Jul 27; 547(7664):453-457. PMID: 28678785.
        View in: PubMed
      7. Micalizzi DS, Haber D, Maheswaran S. Cancer metastasis through the prism of epithelial-to-mesenchymal transition in circulating tumor cells. Mol Oncol. 2017 Jul; 11(7):770-780. PMID: 28544498.
        View in: PubMed
      8. Au SH, Edd J, Stoddard AE, Wong KHK, Fachin F, Maheswaran S, Haber D, Stott SL, Kapur R, Toner M. Microfluidic Isolation of Circulating Tumor Cell Clusters by Size and Asymmetry. Sci Rep. 2017 May 26; 7(1):2433. PMID: 28550299.
        View in: PubMed
      9. Miyamoto DT, Ting DT, Toner M, Maheswaran S, Haber D. Single-Cell Analysis of Circulating Tumor Cells as a Window into Tumor Heterogeneity. Cold Spring Harb Symp Quant Biol. 2016; 81:269-274. PMID: 28389596.
        View in: PubMed
      10. Zheng Y, Miyamoto DT, Wittner BS, Sullivan JP, Aceto N, Jordan NV, Yu M, Karabacak NM, Comaills V, Morris R, Desai R, Desai N, Emmons E, Milner JD, Lee RJ, Wu CL, Sequist LV, Haas W, Ting DT, Toner M, Ramaswamy S, Maheswaran S, Haber D. Expression of ß-globin by cancer cells promotes cell survival during blood-borne dissemination. Nat Commun. 2017 Feb 09; 8:14344. PMID: 28181495.
        View in: PubMed
      11. Haber D, Burnley PC, Adcock CT, Malchow RL, Marsac KE, Hausrath EM. Modeling background radiation in Southern Nevada. J Environ Radioact. 2017 May; 171:41-64. PMID: 28182978.
        View in: PubMed
      12. Yazinski SA, Comaills V, Buisson R, Genois MM, Nguyen HD, Ho CK, Todorova Kwan T, Morris R, Lauffer S, Nussenzweig A, Ramaswamy S, Benes CH, Haber D, Maheswaran S, Birrer MJ, Zou L. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells. Genes Dev. 2017 Feb 01; 31(3):318-332. PMID: 28242626.
        View in: PubMed
      13. Kalinich M, Bhan I, Kwan TT, Miyamoto DT, Javaid S, LiCausi JA, Milner JD, Hong X, Goyal L, Sil S, Choz M, Ho U, Kapur R, Muzikansky A, Zhang H, Weitz DA, Sequist LV, Ryan DP, Chung RT, Zhu AX, Isselbacher KJ, Ting DT, Toner M, Maheswaran S, Haber D. An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma. Proc Natl Acad Sci U S A. 2017 Jan 31; 114(5):1123-1128. PMID: 28096363.
        View in: PubMed
      14. Comaills V, Kabeche L, Morris R, Buisson R, Yu M, Madden MW, LiCausi JA, Boukhali M, Tajima K, Pan S, Aceto N, Sil S, Zheng Y, Sundaresan T, Yae T, Jordan NV, Miyamoto DT, Ting DT, Ramaswamy S, Haas W, Zou L, Haber D, Maheswaran S. Genomic Instability Is Induced by Persistent Proliferation of Cells Undergoing Epithelial-to-Mesenchymal Transition. Cell Rep. 2016 Dec 06; 17(10):2632-2647. PMID: 27926867.
        View in: PubMed
      15. Haber D, Malchow RL, Burnley PC. Monte Carlo simulations of the gamma-ray exposure rates of common rocks. J Environ Radioact. 2017 Feb; 167:20-25. PMID: 27890299.
        View in: PubMed
      16. Marsac KE, Burnley PC, Adcock CT, Haber D, Malchow RL, Hausrath EM. Modeling background radiation using geochemical data: A case study in and around Cameron, Arizona. J Environ Radioact. 2016 Dec; 165:68-85. PMID: 27640123.
        View in: PubMed
      17. Jordan NV, Bardia A, Wittner BS, Benes C, Ligorio M, Zheng Y, Yu M, Sundaresan TK, Licausi JA, Desai R, O'Keefe RM, Ebright RY, Boukhali M, Sil S, Onozato ML, Iafrate AJ, Kapur R, Sgroi D, Ting DT, Toner M, Ramaswamy S, Haas W, Maheswaran S, Haber D. HER2 expression identifies dynamic functional states within circulating breast cancer cells. Nature. 2016 09 01; 537(7618):102-106. PMID: 27556950.
        View in: PubMed
      18. Iorio F, Knijnenburg TA, Vis DJ, Bignell GR, Menden MP, Schubert M, Aben N, Gonçalves E, Barthorpe S, Lightfoot H, Cokelaer T, Greninger P, van Dyk E, Chang H, de Silva H, Heyn H, Deng X, Egan RK, Liu Q, Mironenko T, Mitropoulos X, Richardson L, Wang J, Zhang T, Moran S, Sayols S, Soleimani M, Tamborero D, Lopez-Bigas N, Ross-Macdonald P, Esteller M, Gray NS, Haber D, Stratton MR, Benes CH, Wessels LFA, Saez-Rodriguez J, McDermott U, Garnett MJ. A Landscape of Pharmacogenomic Interactions in Cancer. Cell. 2016 Jul 28; 166(3):740-754. PMID: 27397505; PMCID: PMC4967469.
      19. Au SH, Storey BD, Moore JC, Tang Q, Chen YL, Javaid S, Sarioglu AF, Sullivan R, Madden MW, O'Keefe R, Haber D, Maheswaran S, Langenau DM, Stott SL, Toner M. Clusters of circulating tumor cells traverse capillary-sized vessels. Proc Natl Acad Sci U S A. 2016 May 03; 113(18):4947-52. PMID: 27091969; PMCID: PMC4983862.
      20. Indolfi L, Ligorio M, Ting DT, Xega K, Tzafriri AR, Bersani F, Aceto N, Thapar V, Fuchs BC, Deshpande V, Baker AB, Ferrone CR, Haber D, Langer R, Clark JW, Edelman ER. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma. Biomaterials. 2016 Jul; 93:71-82. PMID: 27082874; PMCID: PMC4849535 [Available on 07/01/17].
      21. Wong KH, Sandlin RD, Carey TR, Miller KL, Shank AT, Oklu R, Maheswaran S, Haber D, Irimia D, Stott SL, Toner M. The Role of Physical Stabilization in Whole Blood Preservation. Sci Rep. 2016 Feb 15; 6:21023. PMID: 26876805; PMCID: PMC4753451.
      22. Rees MG, Seashore-Ludlow B, Cheah JH, Adams DJ, Price EV, Gill S, Javaid S, Coletti ME, Jones VL, Bodycombe NE, Soule CK, Alexander B, Li A, Montgomery P, Kotz JD, Hon CS, Munoz B, Liefeld T, Dancík V, Haber D, Clish CB, Bittker JA, Palmer M, Wagner BK, Clemons PA, Shamji AF, Schreiber SL. Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Nat Chem Biol. 2016 Feb; 12(2):109-16. PMID: 26656090; PMCID: PMC4718762.
      23. Sundaresan TK, Haber D. Fantastic voyage: the future of cancer diagnostics. Lancet Oncol. 2015 Dec; 16(16):1596-8. PMID: 26678190.
        View in: PubMed
      24. Maheswaran S, Haber D. Cell fate: Transition loses its invasive edge. Nature. 2015 Nov 26; 527(7579):452-3. PMID: 26560026.
        View in: PubMed
      25. Bersani F, Lee E, Kharchenko PV, Xu AW, Liu M, Xega K, MacKenzie OC, Brannigan BW, Wittner BS, Jung H, Ramaswamy S, Park PJ, Maheswaran S, Ting DT, Haber D. Pericentromeric satellite repeat expansions through RNA-derived DNA intermediates in cancer. Proc Natl Acad Sci U S A. 2015 Dec 08; 112(49):15148-53. PMID: 26575630; PMCID: PMC4679016.
      26. Friedman AA, Amzallag A, Pruteanu-Malinici I, Baniya S, Cooper ZA, Piris A, Hargreaves L, Igras V, Frederick DT, Lawrence DP, Haber D, Flaherty KT, Wargo JA, Ramaswamy S, Benes CH, Fisher DE. Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment. PLoS One. 2015; 10(10):e0140310. PMID: 26461489; PMCID: PMC4604168.
      27. Sundaresan TK, Sequist LV, Heymach JV, Riely GJ, Jänne PA, Koch WH, Sullivan JP, Fox DB, Maher R, Muzikansky A, Webb A, Tran HT, Giri U, Fleisher M, Yu HA, Wei W, Johnson BE, Barber TA, Walsh JR, Engelman JA, Stott SL, Kapur R, Maheswaran S, Toner M, Haber D. Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses. Clin Cancer Res. 2016 Mar 01; 22(5):1103-10. PMID: 26446944; PMCID: PMC4775471 [Available on 03/01/17].
      28. Miyamoto DT, Zheng Y, Wittner BS, Lee RJ, Zhu H, Broderick KT, Desai R, Fox DB, Brannigan BW, Trautwein J, Arora KS, Desai N, Dahl DM, Sequist LV, Smith MR, Kapur R, Wu CL, Shioda T, Ramaswamy S, Ting DT, Toner M, Maheswaran S, Haber D. RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science. 2015 Sep 18; 349(6254):1351-6. PMID: 26383955; PMCID: PMC4872391.
      29. Sundaresan TK, Haber D. Does molecular monitoring matter in early-stage breast cancer? Sci Transl Med. 2015 Aug 26; 7(302):302fs35. PMID: 26311727.
        View in: PubMed
      30. Kojic N, Miloševic M, Petrovic D, Isailovic V, Sarioglu AF, Haber D, Kojic M, Toner M. A computational study of circulating large tumor cells traversing microvessels. Comput Biol Med. 2015 Aug; 63:187-95. PMID: 26093786; PMCID: PMC4819961.
      31. Martel JM, Smith KC, Dlamini M, Pletcher K, Yang J, Karabacak M, Haber D, Kapur R, Toner M. Continuous Flow Microfluidic Bioparticle Concentrator. Sci Rep. 2015 Jun 10; 5:11300. PMID: 26061253; PMCID: PMC4462155.
      32. Maheswaran S, Haber D. Ex Vivo Culture of CTCs: An Emerging Resource to Guide Cancer Therapy. Cancer Res. 2015 Jun 15; 75(12):2411-5. PMID: 25998619; PMCID: PMC4470788.
      33. Sarioglu AF, Aceto N, Kojic N, Donaldson MC, Zeinali M, Hamza B, Engstrom A, Zhu H, Sundaresan TK, Miyamoto DT, Luo X, Bardia A, Wittner BS, Ramaswamy S, Shioda T, Ting DT, Stott SL, Kapur R, Maheswaran S, Haber D, Toner M. A microfluidic device for label-free, physical capture of circulating tumor cell clusters. Nat Methods. 2015 Jul; 12(7):685-91. PMID: 25984697; PMCID: PMC4490017.
      34. Kim WJ, Wittner BS, Amzallag A, Brannigan BW, Ting DT, Ramaswamy S, Maheswaran S, Haber D. The WTX Tumor Suppressor Interacts with the Transcriptional Corepressor TRIM28. J Biol Chem. 2015 Jun 05; 290(23):14381-90. PMID: 25882849; PMCID: PMC4505506.
      35. Rothenberg SM, Concannon K, Cullen S, Boulay G, Turke AB, Faber AC, Lockerman EL, Rivera MN, Engelman JA, Maheswaran S, Haber D. Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways. Elife. 2015 Feb 16; 4. PMID: 25686219; PMCID: PMC4384750.
      36. Javaid S, Zhang J, Smolen GA, Yu M, Wittner BS, Singh A, Arora KS, Madden MW, Desai R, Zubrowski MJ, Schott BJ, Ting DT, Stott SL, Toner M, Maheswaran S, Shioda T, Ramaswamy S, Haber D. MAPK7 Regulates EMT Features and Modulates the Generation of CTCs. Mol Cancer Res. 2015 May; 13(5):934-43. PMID: 25678598; PMCID: PMC4433453.
      37. Flynn RL, Cox KE, Jeitany M, Wakimoto H, Bryll AR, Ganem NJ, Bersani F, Pineda JR, Suvà ML, Benes CH, Haber D, Boussin FD, Zou L. Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. Science. 2015 Jan 16; 347(6219):273-7. PMID: 25593184; PMCID: PMC4358324.
      38. Reátegui E, Aceto N, Lim EJ, Sullivan JP, Jensen AE, Zeinali M, Martel JM, Aranyosi AJ, Li W, Castleberry S, Bardia A, Sequist LV, Haber D, Maheswaran S, Hammond PT, Toner M, Stott SL. Tunable nanostructured coating for the capture and selective release of viable circulating tumor cells. Adv Mater. 2015 Mar 04; 27(9):1593-9. PMID: 25640006; PMCID: PMC4492283.
      39. Liu Y, Asnani A, Zou L, Bentley VL, Yu M, Wang Y, Dellaire G, Sarkar KS, Dai M, Chen HH, Sosnovik DE, Shin JT, Haber D, Berman JN, Chao W, Peterson RT. Visnagin protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase. Sci Transl Med. 2014 Dec 10; 6(266):266ra170. PMID: 25504881; PMCID: PMC4360984.
      40. Choy E, Butrynski JE, Harmon DC, Morgan JA, George S, Wagner AJ, D'Adamo D, Cote GM, Flamand Y, Benes CH, Haber D, Baselga JM, Demetri GD. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer. 2014 Nov 05; 14:813. PMID: 25374341; PMCID: PMC4230717.
      41. Bersani F, Lee J, Yu M, Morris R, Desai R, Ramaswamy S, Toner M, Haber D, Parekkadan B. Bioengineered implantable scaffolds as a tool to study stromal-derived factors in metastatic cancer models. Cancer Res. 2014 Dec 15; 74(24):7229-38. PMID: 25339351; PMCID: PMC4267901.
      42. Ting DT, Wittner BS, Ligorio M, Vincent Jordan N, Shah AM, Miyamoto DT, Aceto N, Bersani F, Brannigan BW, Xega K, Ciciliano JC, Zhu H, MacKenzie OC, Trautwein J, Arora KS, Shahid M, Ellis HL, Qu N, Bardeesy N, Rivera MN, Deshpande V, Ferrone CR, Kapur R, Ramaswamy S, Shioda T, Toner M, Maheswaran S, Haber D. Single-cell RNA sequencing identifies extracellular matrix gene expression by pancreatic circulating tumor cells. Cell Rep. 2014 Sep 25; 8(6):1905-18. PMID: 25242334; PMCID: PMC4230325.
      43. Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA, Yu M, Pely A, Engstrom A, Zhu H, Brannigan BW, Kapur R, Stott SL, Shioda T, Ramaswamy S, Ting DT, Lin CP, Toner M, Haber D, Maheswaran S. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014 Aug 28; 158(5):1110-1122. PMID: 25171411; PMCID: PMC4149753.
      44. Sullivan JP, Nahed BV, Madden MW, Oliveira SM, Springer S, Bhere D, Chi AS, Wakimoto H, Rothenberg SM, Sequist LV, Kapur R, Shah K, Iafrate AJ, Curry WT, Loeffler JS, Batchelor TT, Louis DN, Toner M, Maheswaran S, Haber D. Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discov. 2014 Nov; 4(11):1299-309. PMID: 25139148; PMCID: PMC4221467.
      45. Wong IY, Javaid S, Wong EA, Perk S, Haber D, Toner M, Irimia D. Collective and individual migration following the epithelial-mesenchymal transition. Nat Mater. 2014 Nov; 13(11):1063-71. PMID: 25129619; PMCID: PMC4209198.
      46. Bardia A, Haber D. Solidifying liquid biopsies: can circulating tumor cell monitoring guide treatment selection in breast cancer? J Clin Oncol. 2014 Nov 01; 32(31):3470-1. PMID: 25024075.
        View in: PubMed
      47. Yu M, Bardia A, Aceto N, Bersani F, Madden MW, Donaldson MC, Desai R, Zhu H, Comaills V, Zheng Z, Wittner BS, Stojanov P, Brachtel E, Sgroi D, Kapur R, Shioda T, Ting DT, Ramaswamy S, Getz G, Iafrate AJ, Benes C, Toner M, Maheswaran S, Haber D. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science. 2014 Jul 11; 345(6193):216-20. PMID: 25013076; PMCID: PMC4358808.
      48. Schrader KA, Stratton KL, Murali R, Laitman Y, Cavallone L, Offit L, Wen YH, Thomas T, Shah S, Rau-Murthy R, Manschreck C, Salo-Mullen E, Otegbeye E, Corines M, Zhang L, Norton L, Hudis C, Klein RJ, Kauff ND, Robson M, Stadler ZK, Haber D, Lipkin SM, Friedman E, Foulkes WD, Altshuler D, Vijai J, Offit K. Genome Sequencing of Multiple Primary Tumors Reveals a Novel PALB2 Variant. J Clin Oncol. 2016 Mar 10; 34(8):e61-7. PMID: 24982446.
        View in: PubMed
      49. Haber D, Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov. 2014 Jun; 4(6):650-61. PMID: 24801577; PMCID: PMC4433544.
      50. Luo X, Mitra D, Sullivan RJ, Wittner BS, Kimura AM, Pan S, Hoang MP, Brannigan BW, Lawrence DP, Flaherty KT, Sequist LV, McMahon M, Bosenberg MW, Stott SL, Ting DT, Ramaswamy S, Toner M, Fisher DE, Maheswaran S, Haber D. Isolation and molecular characterization of circulating melanoma cells. Cell Rep. 2014 May 08; 7(3):645-53. PMID: 24746818; PMCID: PMC4079008.
      51. Karabacak NM, Spuhler PS, Fachin F, Lim EJ, Pai V, Ozkumur E, Martel JM, Kojic N, Smith K, Chen PI, Yang J, Hwang H, Morgan B, Trautwein J, Barber TA, Stott SL, Maheswaran S, Kapur R, Haber D, Toner M. Microfluidic, marker-free isolation of circulating tumor cells from blood samples. Nat Protoc. 2014 Mar; 9(3):694-710. PMID: 24577360; PMCID: PMC4179254.
      52. Javaid S, Zhang J, Anderssen E, Black JC, Wittner BS, Tajima K, Ting DT, Smolen GA, Zubrowski M, Desai R, Maheswaran S, Ramaswamy S, Whetstine JR, Haber D. Dynamic chromatin modification sustains epithelial-mesenchymal transition following inducible expression of Snail-1. Cell Rep. 2013 Dec 26; 5(6):1679-89. PMID: 24360956; PMCID: PMC4034764.
      53. Burger A, Vasilyev A, Tomar R, Selig MK, Nielsen GP, Peterson RT, Drummond IA, Haber D. A zebrafish model of chordoma initiated by notochord-driven expression of HRASV12. Dis Model Mech. 2014 Jul; 7(7):907-13. PMID: 24311731; PMCID: PMC4073279.
      54. Liu M, Roth A, Yu M, Morris R, Bersani F, Rivera MN, Lu J, Shioda T, Vasudevan S, Ramaswamy S, Maheswaran S, Diederichs S, Haber D. The IGF2 intronic miR-483 selectively enhances transcription from IGF2 fetal promoters and enhances tumorigenesis. Genes Dev. 2013 Dec 01; 27(23):2543-8. PMID: 24298054; PMCID: PMC3861668.
      55. Akhavanfard S, Vargas SO, Han M, Nitta M, Chang CB, Le LP, Fazlollahi L, Nguyen Q, Ma Y, Cosper A, Dias-Santagata D, Han JY, Bergethon K, Borger DR, Ellisen LW, Pomeroy SL, Haber D, Iafrate AJ, Rivera MN. Inactivation of the tumor suppressor WTX in a subset of pediatric tumors. Genes Chromosomes Cancer. 2014 Jan; 53(1):67-77. PMID: 24249259.
        View in: PubMed
      56. Corcoran RB, Rothenberg SM, Hata AN, Faber AC, Piris A, Nazarian RM, Brown RD, Godfrey JT, Winokur D, Walsh J, Mino-Kenudson M, Maheswaran S, Settleman J, Wargo JA, Flaherty KT, Haber D, Engelman JA. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci Transl Med. 2013 Jul 31; 5(196):196ra98. PMID: 23903755; PMCID: PMC3867020.
      57. Horning SJ, Haber D, Selig WK, Ivy SP, Roberts SA, Allen JD, Sigal EV, Sawyers CL. Developing standards for breakthrough therapy designation in oncology. Clin Cancer Res. 2013 Aug 15; 19(16):4297-304. PMID: 23719260; PMCID: PMC3745545.
      58. Ozkumur E, Shah AM, Ciciliano JC, Emmink BL, Miyamoto DT, Brachtel E, Yu M, Chen PI, Morgan B, Trautwein J, Kimura A, Sengupta S, Stott SL, Karabacak NM, Barber TA, Walsh JR, Smith K, Spuhler PS, Sullivan JP, Lee RJ, Ting DT, Luo X, Shaw AT, Bardia A, Sequist LV, Louis DN, Maheswaran S, Kapur R, Haber D, Toner M. Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med. 2013 Apr 03; 5(179):179ra47. PMID: 23552373; PMCID: PMC3760275.
      59. Lee RJ, Saylor PJ, Michaelson MD, Rothenberg SM, Smas ME, Miyamoto DT, Gurski CA, Xie W, Maheswaran S, Haber D, Goldin JG, Smith MR. A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clin Cancer Res. 2013 Jun 01; 19(11):3088-94. PMID: 23553848; PMCID: PMC3684567.
      60. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, Concannon KF, Donaldson MC, Sequist LV, Brachtel E, Sgroi D, Baselga J, Ramaswamy S, Toner M, Haber D, Maheswaran S. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013 Feb 01; 339(6119):580-4. PMID: 23372014; PMCID: PMC3760262.
      61. Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, Bindal N, Beare D, Smith JA, Thompson IR, Ramaswamy S, Futreal PA, Haber D, Stratton MR, Benes C, McDermott U, Garnett MJ. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013 Jan; 41(Database issue):D955-61. PMID: 23180760; PMCID: PMC3531057.
      62. Mitra D, Luo X, Morgan A, Wang J, Hoang MP, Lo J, Guerrero CR, Lennerz JK, Mihm MC, Wargo JA, Robinson KC, Devi SP, Vanover JC, D'Orazio JA, McMahon M, Bosenberg MW, Haigis KM, Haber D, Wang Y, Fisher DE. An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature. 2012 Nov 15; 491(7424):449-53. PMID: 23123854; PMCID: PMC3521494.
      63. Miyamoto DT, Lee RJ, Stott SL, Ting DT, Wittner BS, Ulman M, Smas ME, Lord JB, Brannigan BW, Trautwein J, Bander NH, Wu CL, Sequist LV, Smith MR, Ramaswamy S, Toner M, Maheswaran S, Haber D. Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov. 2012 Nov; 2(11):995-1003. PMID: 23093251; PMCID: PMC3508523.
      64. Yu M, Ting DT, Stott SL, Wittner BS, Ozsolak F, Paul S, Ciciliano JC, Smas ME, Winokur D, Gilman AJ, Ulman MJ, Xega K, Contino G, Alagesan B, Brannigan BW, Milos PM, Ryan DP, Sequist LV, Bardeesy N, Ramaswamy S, Toner M, Maheswaran S, Haber D. RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature. 2012 Jul 26; 487(7408):510-3. PMID: 22763454; PMCID: PMC3408856.
      65. Shah AM, Yu M, Nakamura Z, Ciciliano J, Ulman M, Kotz K, Stott SL, Maheswaran S, Haber D, Toner M. Biopolymer system for cell recovery from microfluidic cell capture devices. Anal Chem. 2012 Apr 17; 84(8):3682-8. PMID: 22414137; PMCID: PMC3328665.
      66. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J, Liu Q, Iorio F, Surdez D, Chen L, Milano RJ, Bignell GR, Tam AT, Davies H, Stevenson JA, Barthorpe S, Lutz SR, Kogera F, Lawrence K, McLaren-Douglas A, Mitropoulos X, Mironenko T, Thi H, Richardson L, Zhou W, Jewitt F, Zhang T, O'Brien P, Boisvert JL, Price S, Hur W, Yang W, Deng X, Butler A, Choi HG, Chang JW, Baselga J, Stamenkovic I, Engelman JA, Sharma SV, Delattre O, Saez-Rodriguez J, Gray NS, Settleman J, Futreal PA, Haber D, Stratton MR, Ramaswamy S, McDermott U, Benes CH. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012 Mar 28; 483(7391):570-5. PMID: 22460902; PMCID: PMC3349233.
      67. Singh A, Sweeney MF, Yu M, Burger A, Greninger P, Benes C, Haber D, Settleman J. TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. Cell. 2012 Feb 17; 148(4):639-50. PMID: 22341439; PMCID: PMC3291475.
      68. Kim WJ, Rivera MN, Coffman EJ, Haber D. The WTX tumor suppressor enhances p53 acetylation by CBP/p300. Mol Cell. 2012 Mar 09; 45(5):587-97. PMID: 22285752; PMCID: PMC3310179.
      69. Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Bergethon K, Lauwers GY, Christensen JG, Wilner KD, Haber D, Salgia R, Bang YJ, Clark JW, Solomon BJ, Iafrate AJ. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol. 2011 Dec 20; 29(36):4803-10. PMID: 22042947; PMCID: PMC3255989.
      70. Chiba N, Comaills V, Shiotani B, Takahashi F, Shimada T, Tajima K, Winokur D, Hayashida T, Willers H, Brachtel E, Vivanco MD, Haber D, Zou L, Maheswaran S. Homeobox B9 induces epithelial-to-mesenchymal transition-associated radioresistance by accelerating DNA damage responses. Proc Natl Acad Sci U S A. 2012 Feb 21; 109(8):2760-5. PMID: 21930940; PMCID: PMC3286905.
      71. Haber D, Gray NS, Baselga J. The evolving war on cancer. Cell. 2011 Apr 01; 145(1):19-24. PMID: 21458664.
        View in: PubMed
      72. Yu M, Stott S, Toner M, Maheswaran S, Haber D. Circulating tumor cells: approaches to isolation and characterization. J Cell Biol. 2011 Feb 07; 192(3):373-82. PMID: 21300848; PMCID: PMC3101098.
      73. Ting DT, Lipson D, Paul S, Brannigan BW, Akhavanfard S, Coffman EJ, Contino G, Deshpande V, Iafrate AJ, Letovsky S, Rivera MN, Bardeesy N, Maheswaran S, Haber D. Aberrant overexpression of satellite repeats in pancreatic and other epithelial cancers. Science. 2011 Feb 04; 331(6017):593-6. PMID: 21233348; PMCID: PMC3701432.
      74. Smolen GA, Zhang J, Zubrowski MJ, Edelman EJ, Luo B, Yu M, Ng LW, Scherber CM, Schott BJ, Ramaswamy S, Irimia D, Root DE, Haber D. A genome-wide RNAi screen identifies multiple RSK-dependent regulators of cell migration. Genes Dev. 2010 Dec 01; 24(23):2654-65. PMID: 21062900; PMCID: PMC2994039.
      75. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber D, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010 Oct 28; 363(18):1693-703. PMID: 20979469; PMCID: PMC3014291.
      76. Stott SL, Hsu CH, Tsukrov DI, Yu M, Miyamoto DT, Waltman BA, Rothenberg SM, Shah AM, Smas ME, Korir GK, Floyd FP, Gilman AJ, Lord JB, Winokur D, Springer S, Irimia D, Nagrath S, Sequist LV, Lee RJ, Isselbacher KJ, Maheswaran S, Haber D, Toner M. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A. 2010 Oct 26; 107(43):18392-7. PMID: 20930119; PMCID: PMC2972993.
      77. Ozsolak F, Ting DT, Wittner BS, Brannigan BW, Paul S, Bardeesy N, Ramaswamy S, Milos PM, Haber D. Amplification-free digital gene expression profiling from minute cell quantities. Nat Methods. 2010 Aug; 7(8):619-21. PMID: 20639869; PMCID: PMC2975601.
      78. Wells J, Rivera MN, Kim WJ, Starbuck K, Haber D. The predominant WT1 isoform (+KTS) encodes a DNA-binding protein targeting the planar cell polarity gene Scribble in renal podocytes. Mol Cancer Res. 2010 Jul; 8(7):975-85. PMID: 20571064; PMCID: PMC2905485.
      79. Aiden AP, Rivera MN, Rheinbay E, Ku M, Coffman EJ, Truong TT, Vargas SO, Lander ES, Haber D, Bernstein BE. Wilms tumor chromatin profiles highlight stem cell properties and a renal developmental network. Cell Stem Cell. 2010 Jun 04; 6(6):591-602. PMID: 20569696; PMCID: PMC2897075.
      80. Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, Boisvert SL, Stubbs H, McDermott U, Settleman J, Kwak EL, Clark JW, Isakoff SJ, Sequist LV, Engelman JA, Lynch TJ, Haber D, Louis DN, Ellisen LW, Borger DR, Iafrate AJ. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med. 2010 May; 2(5):146-58. PMID: 20432502; PMCID: PMC3377316.
      81. Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L, Inserra EJ, Ulman M, Springer S, Nakamura Z, Moore AL, Tsukrov DI, Kempner ME, Dahl DM, Wu CL, Iafrate AJ, Smith MR, Tompkins RG, Sequist LV, Toner M, Haber D, Maheswaran S. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med. 2010 Mar 31; 2(25):25ra23. PMID: 20424012; PMCID: PMC3141292.
      82. Sharma SV, Haber D, Settleman J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer. 2010 Apr; 10(4):241-53. PMID: 20300105.
        View in: PubMed
      83. Rothenberg SM, Mohapatra G, Rivera MN, Winokur D, Greninger P, Nitta M, Sadow PM, Sooriyakumar G, Brannigan BW, Ulman MJ, Perera RM, Wang R, Tam A, Ma XJ, Erlander M, Sgroi DC, Rocco JW, Lingen MW, Cohen EE, Louis DN, Settleman J, Haber D. A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers. Cancer Res. 2010 Mar 15; 70(6):2158-64. PMID: 20215515; PMCID: PMC2881662.
      84. Maheswaran S, Haber D. Circulating tumor cells: a window into cancer biology and metastasis. Curr Opin Genet Dev. 2010 Feb; 20(1):96-9. PMID: 20071161; PMCID: PMC2846729.
      85. Zhang J, Ji JY, Yu M, Overholtzer M, Smolen GA, Wang R, Brugge JS, Dyson NJ, Haber D. YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway. Nat Cell Biol. 2009 Dec; 11(12):1444-50. PMID: 19935651; PMCID: PMC2819909.
      86. Zhang J, Song YH, Brannigan BW, Wahrer DC, Schiripo TA, Harris PL, Haserlat SM, Ulkus LE, Shannon KM, Garber JE, Freedman ML, Henderson BE, Zou L, Sgroi DC, Haber D, Bell DW. Prevalence and functional analysis of sequence variants in the ATR checkpoint mediator Claspin. Mol Cancer Res. 2009 Sep; 7(9):1510-6. PMID: 19737971; PMCID: PMC2994259.
      87. Yu M, Smolen GA, Zhang J, Wittner B, Schott BJ, Brachtel E, Ramaswamy S, Maheswaran S, Haber D. A developmentally regulated inducer of EMT, LBX1, contributes to breast cancer progression. Genes Dev. 2009 Aug 01; 23(15):1737-42. PMID: 19651985; PMCID: PMC2720264.
      88. Rivera MN, Kim WJ, Wells J, Stone A, Burger A, Coffman EJ, Zhang J, Haber D. The tumor suppressor WTX shuttles to the nucleus and modulates WT1 activity. Proc Natl Acad Sci U S A. 2009 May 19; 106(20):8338-43. PMID: 19416806; PMCID: PMC2677091.
      89. McDermott U, Ames RY, Iafrate AJ, Maheswaran S, Stubbs H, Greninger P, McCutcheon K, Milano R, Tam A, Lee DY, Lucien L, Brannigan BW, Ulkus LE, Ma XJ, Erlander MG, Haber D, Sharma SV, Settleman J. Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors. Cancer Res. 2009 May 01; 69(9):3937-46. PMID: 19366796; PMCID: PMC2676215.
      90. Sequist LV, Nagrath S, Toner M, Haber D, Lynch TJ. The CTC-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients. J Thorac Oncol. 2009 Mar; 4(3):281-3. PMID: 19247082; PMCID: PMC4486079.
      91. Chin TM, Quinlan MP, Singh A, Sequist LV, Lynch TJ, Haber D, Sharma SV, Settleman J. Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment. Clin Cancer Res. 2008 Nov 01; 14(21):6867-76. PMID: 18980981; PMCID: PMC2710881.
      92. Kim S, Mohapatra G, Haber D. In vitro phosphorylation of BRCA2 by the checkpoint kinase CHEK2. Br J Cancer. 2008 Oct 21; 99(8):1302-6. PMID: 18797466; PMCID: PMC2570522.
      93. Rothenberg SM, Engelman JA, Le S, Riese DJ, Haber D, Settleman J. Modeling oncogene addiction using RNA interference. Proc Natl Acad Sci U S A. 2008 Aug 26; 105(34):12480-4. PMID: 18711136; PMCID: PMC2517605.
      94. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, Inserra E, Diederichs S, Iafrate AJ, Bell DW, Digumarthy S, Muzikansky A, Irimia D, Settleman J, Tompkins RG, Lynch TJ, Toner M, Haber D. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 2008 Jul 24; 359(4):366-77. PMID: 18596266; PMCID: PMC3551471.
      95. Bell DW, Brannigan BW, Matsuo K, Finkelstein DM, Sordella R, Settleman J, Mitsudomi T, Haber D. Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms. Clin Cancer Res. 2008 Jul 01; 14(13):4079-84. PMID: 18593984; PMCID: PMC3391698.
      96. Diederichs S, Jung S, Rothenberg SM, Smolen GA, Mlody BG, Haber D. Coexpression of Argonaute-2 enhances RNA interference toward perfect match binding sites. Proc Natl Acad Sci U S A. 2008 Jul 08; 105(27):9284-9. PMID: 18591665; PMCID: PMC2442125.
      97. Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE, Dias-Santagata D, Stubbs H, Lee DY, Singh A, Drew L, Haber D, Settleman J. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 2008 Jun 15; 68(12):4853-61. PMID: 18559533; PMCID: PMC2692356.
      98. Li H, Smolen GA, Beers LF, Xia L, Gerald W, Wang J, Haber D, Lee SB. Adenosine transporter ENT4 is a direct target of EWS/WT1 translocation product and is highly expressed in desmoplastic small round cell tumor. PLoS One. 2008 Jun 04; 3(6):e2353. PMID: 18523561; PMCID: PMC2394657.
      99. Wittner BS, Sgroi DC, Ryan PD, Bruinsma TJ, Glas AM, Male A, Dahiya S, Habin K, Bernards R, Haber D, Van't Veer LJ, Ramaswamy S. Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort. Clin Cancer Res. 2008 May 15; 14(10):2988-93. PMID: 18483364; PMCID: PMC3089800.
      100. Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber D, Johnson BE, Lynch TJ. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol. 2008 May 20; 26(15):2442-9. PMID: 18458038.
        View in: PubMed
      101. McDermott U, Iafrate AJ, Gray NS, Shioda T, Classon M, Maheswaran S, Zhou W, Choi HG, Smith SL, Dowell L, Ulkus LE, Kuhlmann G, Greninger P, Christensen JG, Haber D, Settleman J. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res. 2008 May 01; 68(9):3389-95. PMID: 18451166.
        View in: PubMed
      102. Zhang J, Smolen GA, Haber D. Negative regulation of YAP by LATS1 underscores evolutionary conservation of the Drosophila Hippo pathway. Cancer Res. 2008 Apr 15; 68(8):2789-94. PMID: 18413746.
        View in: PubMed
      103. Godin-Heymann N, Ulkus L, Brannigan BW, McDermott U, Lamb J, Maheswaran S, Settleman J, Haber D. The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Mol Cancer Ther. 2008 Apr; 7(4):874-9. PMID: 18413800.
        View in: PubMed
      104. Kim WJ, Okimoto RA, Purton LE, Goodwin M, Haserlat SM, Dayyani F, Sweetser DA, McClatchey AI, Bernard OA, Look AT, Bell DW, Scadden DT, Haber D. Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias. Blood. 2008 May 01; 111(9):4716-22. PMID: 18299447; PMCID: PMC2343601.
      105. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky A, Ryan P, Balis UJ, Tompkins RG, Haber D, Toner M. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007 Dec 20; 450(7173):1235-9. PMID: 18097410; PMCID: PMC3090667.
      106. Bell DW, Kim SH, Godwin AK, Schiripo TA, Harris PL, Haserlat SM, Wahrer DC, Haiman CA, Daly MB, Niendorf KB, Smith MR, Sgroi DC, Garber JE, Olopade OI, Le Marchand L, Henderson BE, Altshuler D, Haber D, Freedman ML. Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Int J Cancer. 2007 Dec 15; 121(12):2661-7. PMID: 17721994; PMCID: PMC3090684.
      107. Diederichs S, Haber D. Dual role for argonautes in microRNA processing and posttranscriptional regulation of microRNA expression. Cell. 2007 Dec 14; 131(6):1097-108. PMID: 18083100.
        View in: PubMed
      108. McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, Archibald H, Raudales R, Tam A, Lee D, Rothenberg SM, Supko JG, Sordella R, Ulkus LE, Iafrate AJ, Maheswaran S, Njauw CN, Tsao H, Drew L, Hanke JH, Ma XJ, Erlander MG, Gray NS, Haber D, Settleman J. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A. 2007 Dec 11; 104(50):19936-41. PMID: 18077425; PMCID: PMC2148401.
      109. Han M, Rivera MN, Batten JM, Haber D, Dal Cin P, Iafrate AJ. Wilms' tumor with an apparently balanced translocation t(X;18) resulting in deletion of the WTX gene. Genes Chromosomes Cancer. 2007 Oct; 46(10):909-13. PMID: 17620295.
        View in: PubMed
      110. Smolen GA, Schott BJ, Stewart RA, Diederichs S, Muir B, Provencher HL, Look AT, Sgroi DC, Peterson RT, Haber D. A Rap GTPase interactor, RADIL, mediates migration of neural crest precursors. Genes Dev. 2007 Sep 01; 21(17):2131-6. PMID: 17704304; PMCID: PMC1950852.
      111. Godin-Heymann N, Bryant I, Rivera MN, Ulkus L, Bell DW, Riese DJ, Settleman J, Haber D. Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. Cancer Res. 2007 Aug 01; 67(15):7319-26. PMID: 17671201; PMCID: PMC2882853.
      112. Haber D, Settleman J. Cancer: drivers and passengers. Nature. 2007 Mar 08; 446(7132):145-6. PMID: 17344839.
        View in: PubMed
      113. Mulloy R, Ferrand A, Kim Y, Sordella R, Bell DW, Haber D, Anderson KS, Settleman J. Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res. 2007 Mar 01; 67(5):2325-30. PMID: 17332364.
        View in: PubMed
      114. Sharma SV, Bell DW, Settleman J, Haber D. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007 Mar; 7(3):169-81. PMID: 17318210.
        View in: PubMed
      115. Sequist LV, Bell DW, Lynch TJ, Haber D. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol. 2007 Feb 10; 25(5):587-95. PMID: 17290067.
        View in: PubMed
      116. Erkko H, Xia B, Nikkilä J, Schleutker J, Syrjäkoski K, Mannermaa A, Kallioniemi A, Pylkäs K, Karppinen SM, Rapakko K, Miron A, Sheng Q, Li G, Mattila H, Bell DW, Haber D, Grip M, Reiman M, Jukkola-Vuorinen A, Mustonen A, Kere J, Aaltonen LA, Kosma VM, Kataja V, Soini Y, Drapkin RI, Livingston DM, Winqvist R. A recurrent mutation in PALB2 in Finnish cancer families. Nature. 2007 Mar 15; 446(7133):316-9. PMID: 17287723.
        View in: PubMed
      117. Rivera MN, Kim WJ, Wells J, Driscoll DR, Brannigan BW, Han M, Kim JC, Feinberg AP, Gerald WL, Vargas SO, Chin L, Iafrate AJ, Bell DW, Haber D. An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science. 2007 Feb 02; 315(5812):642-5. PMID: 17204608.
        View in: PubMed
      118. Sequist LV, Joshi VA, Jänne PA, Muzikansky A, Fidias P, Meyerson M, Haber D, Kucherlapati R, Johnson BE, Lynch TJ. Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist. 2007 Jan; 12(1):90-8. PMID: 17285735.
        View in: PubMed
      119. Sharma SV, Gajowniczek P, Way IP, Lee DY, Jiang J, Yuza Y, Classon M, Haber D, Settleman J. A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell. 2006 Nov; 10(5):425-35. PMID: 17097564; PMCID: PMC2673136.
      120. Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, Sgroi DC, Deng CX, Brugge JS, Haber D. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A. 2006 Aug 15; 103(33):12405-10. PMID: 16894141; PMCID: PMC1533802.
      121. Sequist LV, Joshi VA, Jänne PA, Bell DW, Fidias P, Lindeman NI, Louis DN, Lee JC, Mark EJ, Longtine J, Verlander P, Kucherlapati R, Meyerson M, Haber D, Johnson BE, Lynch TJ. Epidermal growth factor receptor mutation testing in the care of lung cancer patients. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 2):4403s-4408s. PMID: 16857818.
        View in: PubMed
      122. Kwak EL, Jankowski J, Thayer SP, Lauwers GY, Brannigan BW, Harris PL, Okimoto RA, Haserlat SM, Driscoll DR, Ferry D, Muir B, Settleman J, Fuchs CS, Kulke MH, Ryan DP, Clark JW, Sgroi DC, Haber D, Bell DW. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 1):4283-7. PMID: 16857803; PMCID: PMC3807136.
      123. Lynch TJ, Adjei AA, Bunn PA, Eisen TG, Engelman J, Goss GD, Haber D, Heymach JV, Jänne PA, Johnson BE, Johnson DH, Lilenbaum RC, Meyerson M, Sandler AB, Sequist LV, Settleman J, Wong KK, Hart CS. Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 2):4365s-4371s. PMID: 16857812.
        View in: PubMed
      124. Sharma SV, Fischbach MA, Haber D, Settleman J. "Oncogenic shock": explaining oncogene addiction through differential signal attenuation. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 2):4392s-4395s. PMID: 16857816.
        View in: PubMed
      125. Bell DW, Haber D. A blood-based test for epidermal growth factor receptor mutations in lung cancer. Clin Cancer Res. 2006 Jul 01; 12(13):3875-7. PMID: 16818680.
        View in: PubMed
      126. Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber D, Lynch TJ, Meyerson M, Johnson BE, Jänne PA. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 2006 Jul 01; 12(13):3908-14. PMID: 16818686.
        View in: PubMed
      127. Diederichs S, Haber D. Sequence variations of microRNAs in human cancer: alterations in predicted secondary structure do not affect processing. Cancer Res. 2006 Jun 15; 66(12):6097-104. PMID: 16778182.
        View in: PubMed
      128. Smolen GA, Muir B, Mohapatra G, Barmettler A, Kim WJ, Rivera MN, Haserlat SM, Okimoto RA, Kwak E, Dahiya S, Garber JE, Bell DW, Sgroi DC, Chin L, Deng CX, Haber D. Frequent met oncogene amplification in a Brca1/Trp53 mouse model of mammary tumorigenesis. Cancer Res. 2006 Apr 01; 66(7):3452-5. PMID: 16585167.
        View in: PubMed
      129. Kwak EL, Kim S, Zhang J, Cardiff RD, Schmidt EV, Haber D. Mammary tumorigenesis following transgenic expression of a dominant negative CHK2 mutant. Cancer Res. 2006 Feb 15; 66(4):1923-8. PMID: 16488990; PMCID: PMC2865171.
      130. Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H, Kim WJ, Okimoto RA, Bell DW, Sgroi DC, Christensen JG, Settleman J, Haber D. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A. 2006 Feb 14; 103(7):2316-21. PMID: 16461907; PMCID: PMC1413705.
      131. Cohen EE, Lingen MW, Martin LE, Harris PL, Brannigan BW, Haserlat SM, Okimoto RA, Sgroi DC, Dahiya S, Muir B, Clark JR, Rocco JW, Vokes EE, Haber D, Bell DW. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res. 2005 Nov 15; 11(22):8105-8. PMID: 16299242.
        View in: PubMed
      132. Bell DW, Gore I, Okimoto RA, Godin-Heymann N, Sordella R, Mulloy R, Sharma SV, Brannigan BW, Mohapatra G, Settleman J, Haber D. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet. 2005 Dec; 37(12):1315-6. PMID: 16258541.
        View in: PubMed
      133. Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, Sgroi DC, Muir B, Riemenschneider MJ, Iacona RB, Krebs AD, Johnson DH, Giaccone G, Herbst RS, Manegold C, Fukuoka M, Kris MG, Baselga J, Ochs JS, Haber D. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol. 2005 Nov 01; 23(31):8081-92. PMID: 16204011.
        View in: PubMed
      134. Rivera MN, Haber D. Wilms' tumour: connecting tumorigenesis and organ development in the kidney. Nat Rev Cancer. 2005 Sep; 5(9):699-712. PMID: 16110318.
        View in: PubMed
      135. Haber D, Settleman J. Overcoming acquired resistance to Iressa/Tarceva with inhibitors of a different class. Cell Cycle. 2005 Aug; 4(8):1057-9. PMID: 15970680.
        View in: PubMed
      136. Sequist LV, Haber D, Lynch TJ. Epidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors. Clin Cancer Res. 2005 Aug 15; 11(16):5668-70. PMID: 16115901.
        View in: PubMed
      137. Lorenzen JA, Bonacci BB, Palmer RE, Wells C, Zhang J, Haber D, Goldstein AM, Mayer AN. Rbm19 is a nucleolar protein expressed in crypt/progenitor cells of the intestinal epithelium. Gene Expr Patterns. 2005 Dec; 6(1):45-56. PMID: 16027046.
        View in: PubMed
      138. Kwak EL, Moberg KH, Wahrer DC, Quinn JE, Gilmore PM, Graham CA, Hariharan IK, Harkin DP, Haber D, Bell DW. Infrequent mutations of Archipelago (hAGO, hCDC4, Fbw7) in primary ovarian cancer. Gynecol Oncol. 2005 Jul; 98(1):124-8. PMID: 15913747.
        View in: PubMed
      139. Gerald WL, Haber D. The EWS-WT1 gene fusion in desmoplastic small round cell tumor. Semin Cancer Biol. 2005 Jun; 15(3):197-205. PMID: 15826834.
        View in: PubMed
      140. Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, Harris PL, Driscoll DR, Fidias P, Lynch TJ, Rabindran SK, McGinnis JP, Wissner A, Sharma SV, Isselbacher KJ, Settleman J, Haber D. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A. 2005 May 24; 102(21):7665-70. PMID: 15897464; PMCID: PMC1129023.
      141. Riemenschneider MJ, Bell DW, Haber D, Louis DN. Pulmonary adenocarcinomas with mutant epidermal growth factor receptors. N Engl J Med. 2005 Apr 21; 352(16):1724-5. PMID: 15843680.
        View in: PubMed
      142. Haber D, Bell DW, Sordella R, Kwak EL, Godin-Heymann N, Sharma SV, Lynch TJ, Settleman J. Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. Cold Spring Harb Symp Quant Biol. 2005; 70:419-26. PMID: 16869779.
        View in: PubMed
      143. Sgroi DC, Haber D, Ryan PD, Ma XJ, Erlander MG. RE: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell. 2004 Nov; 6(5):445. PMID: 15542428.
        View in: PubMed
      144. Smolen GA, Vassileva MT, Wells J, Matunis MJ, Haber D. SUMO-1 modification of the Wilms' tumor suppressor WT1. Cancer Res. 2004 Nov 01; 64(21):7846-51. PMID: 15520190.
        View in: PubMed
      145. Song YH, Mirey G, Betson M, Haber D, Settleman J. The Drosophila ATM ortholog, dATM, mediates the response to ionizing radiation and to spontaneous DNA damage during development. Curr Biol. 2004 Aug 10; 14(15):1354-9. PMID: 15296752.
        View in: PubMed
      146. Sordella R, Bell DW, Haber D, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004 Aug 20; 305(5687):1163-7. PMID: 15284455.
        View in: PubMed
      147. Zhang H, Christoforou A, Aravind L, Emmons SW, van den Heuvel S, Haber D. The C. elegans Polycomb gene SOP-2 encodes an RNA binding protein. Mol Cell. 2004 Jun 18; 14(6):841-7. PMID: 15200961.
        View in: PubMed
      148. Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, Muir B, Mohapatra G, Salunga R, Tuggle JT, Tran Y, Tran D, Tassin A, Amon P, Wang W, Wang W, Enright E, Stecker K, Estepa-Sabal E, Smith B, Younger J, Balis U, Michaelson J, Bhan A, Habin K, Baer TM, Brugge J, Haber D, Erlander MG, Sgroi DC. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell. 2004 Jun; 5(6):607-16. PMID: 15193263.
        View in: PubMed
      149. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber D. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004 May 20; 350(21):2129-39. PMID: 15118073.
        View in: PubMed
      150. Zhang H, Smolen GA, Palmer R, Christoforou A, van den Heuvel S, Haber D. SUMO modification is required for in vivo Hox gene regulation by the Caenorhabditis elegans Polycomb group protein SOP-2. Nat Genet. 2004 May; 36(5):507-11. PMID: 15107848.
        View in: PubMed
      151. Gal I, Gershoni Baruch R, Haber D, Dagan E, Eisenberg-Barzilai S, Zidan J, Friedman E. The 1100delAT BRCA1 and the 8765delAG BRCA2 mutations: occurrence in high-risk non-Ashkenazi Jews and haplotype comparison of Jewish and non-Jewish carriers. Fam Cancer. 2004; 3(1):11-4. PMID: 15131400.
        View in: PubMed
      152. Haber D. The BRCA2-EMSY connection: implications for breast and ovarian tumorigenesis. Cell. 2003 Nov 26; 115(5):507-8. PMID: 14651841.
        View in: PubMed
      153. Zhang H, Palmer R, Gao X, Kreidberg J, Gerald W, Hsiao L, Jensen RV, Gullans SR, Haber D. Transcriptional activation of placental growth factor by the forkhead/winged helix transcription factor FoxD1. Curr Biol. 2003 Sep 16; 13(18):1625-9. PMID: 13678594.
        View in: PubMed
      154. Ryan PD, Haber D, Shannon KM, Smith BL, Fan MJ. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 28-2003. A 51-year-old premenopausal woman with newly diagnosed breast cancer and a strong family history of breast cancer. N Engl J Med. 2003 Sep 11; 349(11):1076-82. PMID: 12968092.
        View in: PubMed
      155. Reynolds PA, Smolen GA, Palmer RE, Sgroi D, Yajnik V, Gerald WL, Haber D. Identification of a DNA-binding site and transcriptional target for the EWS-WT1(+KTS) oncoprotein. Genes Dev. 2003 Sep 01; 17(17):2094-107. PMID: 12923058; PMCID: PMC196452.
      156. Lee BC, Cheng T, Adams GB, Attar EC, Miura N, Lee SB, Saito Y, Olszak I, Dombkowski D, Olson DP, Hancock J, Choi PS, Haber D, Luster AD, Scadden DT. P2Y-like receptor, GPR105 (P2Y14), identifies and mediates chemotaxis of bone-marrow hematopoietic stem cells. Genes Dev. 2003 Jul 01; 17(13):1592-604. PMID: 12842911; PMCID: PMC196132.
      157. Hariharan IK, Haber D. Yeast, flies, worms, and fish in the study of human disease. N Engl J Med. 2003 Jun 12; 348(24):2457-63. PMID: 12802034.
        View in: PubMed
      158. Zhang H, Azevedo RB, Lints R, Doyle C, Teng Y, Haber D, Emmons SW. Global regulation of Hox gene expression in C. elegans by a SAM domain protein. Dev Cell. 2003 Jun; 4(6):903-15. PMID: 12791274.
        View in: PubMed
      159. Yajnik V, Paulding C, Sordella R, McClatchey AI, Saito M, Wahrer DC, Reynolds P, Bell DW, Lake R, van den Heuvel S, Settleman J, Haber D. DOCK4, a GTPase activator, is disrupted during tumorigenesis. Cell. 2003 Mar 07; 112(5):673-84. PMID: 12628187.
        View in: PubMed
      160. Paulding CA, Ruvolo M, Haber D. The Tre2 (USP6) oncogene is a hominoid-specific gene. Proc Natl Acad Sci U S A. 2003 Mar 04; 100(5):2507-11. PMID: 12604796; PMCID: PMC151371.
      161. Varley J, Haber D. Familial breast cancer and the hCHK2 1100delC mutation: assessing cancer risk. Breast Cancer Res. 2003; 5(3):123-5. PMID: 12793891; PMCID: PMC164998.
      162. Palmer RE, Lee SB, Wong JC, Reynolds PA, Zhang H, Truong V, Oliner JD, Gerald WL, Haber D. Induction of BAIAP3 by the EWS-WT1 chimeric fusion implicates regulated exocytosis in tumorigenesis. Cancer Cell. 2002 Dec; 2(6):497-505. PMID: 12498718.
        View in: PubMed
      163. Ellisen LW, Ramsayer KD, Johannessen CM, Yang A, Beppu H, Minda K, Oliner JD, McKeon F, Haber D. REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. Mol Cell. 2002 Nov; 10(5):995-1005. PMID: 12453409.
        View in: PubMed
      164. Tapon N, Harvey KF, Bell DW, Wahrer DC, Schiripo TA, Haber D, Hariharan IK. salvador Promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines. Cell. 2002 Aug 23; 110(4):467-78. PMID: 12202036.
        View in: PubMed
      165. Haber D. Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations. N Engl J Med. 2002 May 23; 346(21):1660-2. PMID: 12024000.
        View in: PubMed
      166. Bell DW, Erban J, Sgroi DC, Haber D. Selective loss of heterozygosity in multiple breast cancers from a carrier of mutations in both BRCA1 and BRCA2. Cancer Res. 2002 May 15; 62(10):2741-3. PMID: 12019146.
        View in: PubMed
      167. Andrews HN, Mullan PB, McWilliams S, Sebelova S, Quinn JE, Gilmore PM, McCabe N, Pace A, Koller B, Johnston PG, Haber D, Harkin DP. BRCA1 regulates the interferon gamma-mediated apoptotic response. J Biol Chem. 2002 Jul 19; 277(29):26225-32. PMID: 12011077.
        View in: PubMed
      168. Wong JC, Lee SB, Bell MD, Reynolds PA, Fiore E, Stamenkovic I, Truong V, Oliner JD, Gerald WL, Haber D. Induction of the interleukin-2/15 receptor beta-chain by the EWS-WT1 translocation product. Oncogene. 2002 Mar 27; 21(13):2009-19. PMID: 11960373.
        View in: PubMed
      169. Ravenel JD, Broman KW, Perlman EJ, Niemitz EL, Jayawardena TM, Bell DW, Haber D, Uejima H, Feinberg AP. Loss of imprinting of insulin-like growth factor-II (IGF2) gene in distinguishing specific biologic subtypes of Wilms tumor. J Natl Cancer Inst. 2001 Nov 21; 93(22):1698-703. PMID: 11717330.
        View in: PubMed
      170. Lee SB, Kim SH, Bell DW, Wahrer DC, Schiripo TA, Jorczak MM, Sgroi DC, Garber JE, Li FP, Nichols KE, Varley JM, Godwin AK, Shannon KM, Harlow E, Haber D. Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome. Cancer Res. 2001 Nov 15; 61(22):8062-7. PMID: 11719428.
        View in: PubMed
      171. Palmer RE, Kotsianti A, Cadman B, Boyd T, Gerald W, Haber D. WT1 regulates the expression of the major glomerular podocyte membrane protein Podocalyxin. Curr Biol. 2001 Nov 13; 11(22):1805-9. PMID: 11719225.
        View in: PubMed
      172. Mullan PB, Quinn JE, Gilmore PM, McWilliams S, Andrews H, Gervin C, McCabe N, McKenna S, White P, Song YH, Maheswaran S, Liu E, Haber D, Johnston PG, Harkin DP. BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene. 2001 Sep 27; 20(43):6123-31. PMID: 11593420.
        View in: PubMed
      173. Moberg KH, Bell DW, Wahrer DC, Haber D, Hariharan IK. Archipelago regulates Cyclin E levels in Drosophila and is mutated in human cancer cell lines. Nature. 2001 Sep 20; 413(6853):311-6. PMID: 11565033.
        View in: PubMed
      174. Ellisen LW, Palmer RE, Maki RG, Truong VB, Tamayo P, Oliner JD, Haber D. Cascades of transcriptional induction during human lymphocyte activation. Eur J Cell Biol. 2001 May; 80(5):321-8. PMID: 11432721.
        View in: PubMed
      175. Ellisen LW, Carlesso N, Cheng T, Scadden DT, Haber D. The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells. EMBO J. 2001 Apr 17; 20(8):1897-909. PMID: 11296223; PMCID: PMC125233.
      176. Cantor SB, Bell DW, Ganesan S, Kass EM, Drapkin R, Grossman S, Wahrer DC, Sgroi DC, Lane WS, Haber D, Livingston DM. BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell. 2001 Apr 06; 105(1):149-60. PMID: 11301010.
        View in: PubMed
      177. Lee SB, Haber D. Wilms tumor and the WT1 gene. Exp Cell Res. 2001 Mar 10; 264(1):74-99. PMID: 11237525.
        View in: PubMed
      178. Arico M, Imashuku S, Clementi R, Hibi S, Teramura T, Danesino C, Haber D, Nichols KE. Hemophagocytic lymphohistiocytosis due to germline mutations in SH2D1A, the X-linked lymphoproliferative disease gene. Blood. 2001 Feb 15; 97(4):1131-3. PMID: 11159547.
        View in: PubMed
      179. Wang W, Lee SB, Palmer R, Ellisen LW, Haber D. A functional interaction with CBP contributes to transcriptional activation by the Wilms tumor suppressor WT1. J Biol Chem. 2001 May 18; 276(20):16810-6. PMID: 11278547.
        View in: PubMed
      180. Seth P, Lunetta KL, Bell DW, Gray H, Nasser SM, Rhei E, Kaelin CM, Iglehart DJ, Marks JR, Garber JE, Haber D, Polyak K. Phenol sulfotransferases: hormonal regulation, polymorphism, and age of onset of breast cancer. Cancer Res. 2000 Dec 15; 60(24):6859-63. PMID: 11156380.
        View in: PubMed
      181. Haber D. Roads leading to breast cancer. N Engl J Med. 2000 Nov 23; 343(21):1566-8. PMID: 11087889.
        View in: PubMed
      182. Chaudhuri S, Cariappa A, Tang M, Bell D, Haber D, Isselbacher KJ, Finkelstein D, Forcione D, Pillai S. Genetic susceptibility to breast cancer: HLA DQB*03032 and HLA DRB1*11 may represent protective alleles. Proc Natl Acad Sci U S A. 2000 Oct 10; 97(21):11451-4. PMID: 11027344; PMCID: PMC17220.
      183. Ino Y, Wahrer DC, Bell DW, Haber D, Louis DN. Mutation analysis of the hCHK2 gene in primary human malignant gliomas. Neurogenetics. 2000 Sep; 3(1):45-6. PMID: 11085597.
        View in: PubMed
      184. Haber D. BRCA1: an emerging role in the cellular response to DNA damage. Lancet. 2000 Jun 17; 355(9221):2090-1. PMID: 10902618.
        View in: PubMed
      185. Shafman TD, Levitz S, Nixon AJ, Gibans LA, Nichols KE, Bell DW, Ishioka C, Isselbacher KJ, Gelman R, Garber J, Harris JR, Haber D. Prevalence of germline truncating mutations in ATM in women with a second breast cancer after radiation therapy for a contralateral tumor. Genes Chromosomes Cancer. 2000 Feb; 27(2):124-9. PMID: 10612799.
        View in: PubMed
      186. Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch JM, Li FP, Garber JE, Haber D. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science. 1999 Dec 24; 286(5449):2528-31. PMID: 10617473.
        View in: PubMed
      187. Haber D. Breast cancer in carriers of BRCA1 and BRCA2 mutations: tackling a molecular and clinical conundrum. J Clin Oncol. 1999 Nov; 17(11):3367-70. PMID: 10550129.
        View in: PubMed
      188. Okano M, Bell DW, Haber D, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell. 1999 Oct 29; 99(3):247-57. PMID: 10555141.
        View in: PubMed
      189. Celli J, Duijf P, Hamel BC, Bamshad M, Kramer B, Smits AP, Newbury-Ecob R, Hennekam RC, Van Buggenhout G, van Haeringen A, Woods CG, van Essen AJ, de Waal R, Vriend G, Haber D, Yang A, McKeon F, Brunner HG, van Bokhoven H. Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome. Cell. 1999 Oct 15; 99(2):143-53. PMID: 10535733.
        View in: PubMed
      190. Lee SB, Huang K, Palmer R, Truong VB, Herzlinger D, Kolquist KA, Wong J, Paulding C, Yoon SK, Gerald W, Oliner JD, Haber D. The Wilms tumor suppressor WT1 encodes a transcriptional activator of amphiregulin. Cell. 1999 Sep 03; 98(5):663-73. PMID: 10490105.
        View in: PubMed
      191. Bell DW, Wahrer DC, Kang DH, MacMahon MS, FitzGerald MG, Ishioka C, Isselbacher KJ, Krainer M, Haber D. Common nonsense mutations in RAD52. Cancer Res. 1999 Aug 15; 59(16):3883-8. PMID: 10463575.
        View in: PubMed
      192. Harkin DP, Bean JM, Miklos D, Song YH, Truong VB, Englert C, Christians FC, Ellisen LW, Maheswaran S, Oliner JD, Haber D. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell. 1999 May 28; 97(5):575-86. PMID: 10367887.
        View in: PubMed
      193. Nichols KE, Levitz S, Shannon KE, Wahrer DC, Bell DW, Chang G, Hegde S, Neuberg D, Shafman T, Tarbell NJ, Mauch P, Ishioka C, Haber D, Diller L. Heterozygous germline ATM mutations do not contribute to radiation-associated malignancies after Hodgkin's disease. J Clin Oncol. 1999 Apr; 17(4):1259. PMID: 10561187.
        View in: PubMed
      194. O'Donnell L, Stueve A, San Doval A, Duran R, Haber D, Atnafou R, Johnson N, Grant U, Murray H, Juhn G, Tang J, Piessens P. The effectiveness of the Reach for Health Community Youth Service learning program in reducing early and unprotected sex among urban middle school students. Am J Public Health. 1999 Feb; 89(2):176-81. PMID: 9949745; PMCID: PMC1508549.
      195. O'Donnell L, Stueve A, San Doval A, Duran R, Atnafou R, Haber D, Johnson N, Murray H, Grant U, Juhn G, Tang J, Bass J, Piessens P. Violence prevention and young adolescents' participation in community youth service. J Adolesc Health. 1999 Jan; 24(1):28-37. PMID: 9890362.
        View in: PubMed
      196. Nichols KE, Harkin DP, Levitz S, Krainer M, Kolquist KA, Genovese C, Bernard A, Ferguson M, Zuo L, Snyder E, Buckler AJ, Wise C, Ashley J, Lovett M, Valentine MB, Look AT, Gerald W, Housman DE, Haber D. Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc Natl Acad Sci U S A. 1998 Nov 10; 95(23):13765-70. PMID: 9811875; PMCID: PMC24894.
      197. FitzGerald MG, Marsh DJ, Wahrer D, Bell D, Caron S, Shannon KE, Ishioka C, Isselbacher KJ, Garber JE, Eng C, Haber D. Germline mutations in PTEN are an infrequent cause of genetic predisposition to breast cancer. Oncogene. 1998 Aug 13; 17(6):727-31. PMID: 9715274.
        View in: PubMed
      198. Kolquist KA, Ellisen LW, Counter CM, Meyerson M, Tan LK, Weinberg RA, Haber D, Gerald WL. Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nat Genet. 1998 Jun; 19(2):182-6. PMID: 9620778.
        View in: PubMed
      199. Dahia PL, FitzGerald MG, Zhang X, Marsh DJ, Zheng Z, Pietsch T, von Deimling A, Haluska FG, Haber D, Eng C. A highly conserved processed PTEN pseudogene is located on chromosome band 9p21. Oncogene. 1998 May 07; 16(18):2403-6. PMID: 9620558.
        View in: PubMed
      200. Haber D, Fearon ER. The promise of cancer genetics. Lancet. 1998 May; 351 Suppl 2:SII1-8. PMID: 9606360.
        View in: PubMed
      201. Maheswaran S, Englert C, Lee SB, Ezzel RM, Settleman J, Haber D. E1B 55K sequesters WT1 along with p53 within a cytoplasmic body in adenovirus-transformed kidney cells. Oncogene. 1998 Apr 23; 16(16):2041-50. PMID: 9572485.
        View in: PubMed
      202. Maheswaran S, Englert C, Zheng G, Lee SB, Wong J, Harkin DP, Bean J, Ezzell R, Garvin AJ, McCluskey RT, DeCaprio JA, Haber D. Inhibition of cellular proliferation by the Wilms tumor suppressor WT1 requires association with the inducible chaperone Hsp70. Genes Dev. 1998 Apr 15; 12(8):1108-20. PMID: 9553041; PMCID: PMC316709.
      203. Counter CM, Meyerson M, Eaton EN, Ellisen LW, Caddle SD, Haber D, Weinberg RA. Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene. 1998 Mar 05; 16(9):1217-22. PMID: 9528864.
        View in: PubMed
      204. Nichols KE, Li FP, Haber D, Diller L. Childhood cancer predisposition: applications of molecular testing and future implications. J Pediatr. 1998 Mar; 132(3 Pt 1):389-97. PMID: 9544888.
        View in: PubMed
      205. Ellisen LW, Haber D. Hereditary breast cancer. Annu Rev Med. 1998; 49:425-36. PMID: 9509273.
        View in: PubMed
      206. Pollock PM, Spurr N, Bishop T, Newton-Bishop J, Gruis N, van der Velden PA, Goldstein AM, Tucker MA, Foulkes WD, Barnhill R, Haber D, Fountain J, Hayward NK. Haplotype analysis of two recurrent CDKN2A mutations in 10 melanoma families: evidence for common founders and independent mutations. Hum Mutat. 1998; 11(6):424-31. PMID: 9603434.
        View in: PubMed
      207. Haber D. Splicing into senescence: the curious case of p16 and p19ARF. Cell. 1997 Nov 28; 91(5):555-8. PMID: 9393847.
        View in: PubMed
      208. Lee SB, Kolquist KA, Nichols K, Englert C, Maheswaran S, Ladanyi M, Gerald WL, Haber D. The EWS-WT1 translocation product induces PDGFA in desmoplastic small round-cell tumour. Nat Genet. 1997 Nov; 17(3):309-13. PMID: 9354795.
        View in: PubMed
      209. Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, Ziaugra L, Beijersbergen RL, Davidoff MJ, Liu Q, Bacchetti S, Haber D, Weinberg RA. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell. 1997 Aug 22; 90(4):785-95. PMID: 9288757.
        View in: PubMed
      210. Haber D, Harlow E. Tumour-suppressor genes: evolving definitions in the genomic age. Nat Genet. 1997 Aug; 16(4):320-2. PMID: 9241260.
        View in: PubMed
      211. Krainer M, Silva-Arrieta S, FitzGerald MG, Shimada A, Ishioka C, Kanamaru R, MacDonald DJ, Unsal H, Finkelstein DM, Bowcock A, Isselbacher KJ, Haber D. Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. N Engl J Med. 1997 May 15; 336(20):1416-21. PMID: 9145678.
        View in: PubMed
      212. Englert C, Maheswaran S, Garvin AJ, Kreidberg J, Haber D. Induction of p21 by the Wilms' tumor suppressor gene WT1. Cancer Res. 1997 Apr 15; 57(8):1429-34. PMID: 9108440.
        View in: PubMed
      213. Ishioka C, Suzuki T, FitzGerald M, Krainer M, Shimodaira H, Shimada A, Nomizu T, Isselbacher KJ, Haber D, Kanamaru R. Detection of heterozygous truncating mutations in the BRCA1 and APC genes by using a rapid screening assay in yeast. Proc Natl Acad Sci U S A. 1997 Mar 18; 94(6):2449-53. PMID: 9122215; PMCID: PMC20108.
      214. FitzGerald MG, Bean JM, Hegde SR, Unsal H, MacDonald DJ, Harkin DP, Finkelstein DM, Isselbacher KJ, Haber D. Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet. 1997 Mar; 15(3):307-10. PMID: 9054948.
        View in: PubMed
      215. Johnstone RW, See RH, Sells SF, Wang J, Muthukkumar S, Englert C, Haber D, Licht JD, Sugrue SP, Roberts T, Rangnekar VM, Shi Y. A novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1. Mol Cell Biol. 1996 Dec; 16(12):6945-56. PMID: 8943350; PMCID: PMC231698.
      216. Tonin P, Weber B, Offit K, Couch F, Rebbeck TR, Neuhausen S, Godwin AK, Daly M, Wagner-Costalos J, Berman D, Grana G, Fox E, Kane MF, Kolodner RD, Krainer M, Haber D, Struewing JP, Warner E, Rosen B, Lerman C, Peshkin B, Norton L, Serova O, Foulkes WD, Garber JE. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med. 1996 Nov; 2(11):1179-83. PMID: 8898735.
        View in: PubMed
      217. Haber D, Englert C, Maheswaran S. Functional properties of WT1. Med Pediatr Oncol. 1996 Nov; 27(5):453-5. PMID: 8827073.
        View in: PubMed
      218. FitzGerald MG, Harkin DP, Silva-Arrieta S, MacDonald DJ, Lucchina LC, Unsal H, O'Neill E, Koh J, Finkelstein DM, Isselbacher KJ, Sober AJ, Haber D. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc Natl Acad Sci U S A. 1996 Aug 06; 93(16):8541-5. PMID: 8710906; PMCID: PMC38708.
      219. FitzGerald MG, MacDonald DJ, Krainer M, Hoover I, O'Neil E, Unsal H, Silva-Arrieto S, Finkelstein DM, Beer-Romero P, Englert C, Sgroi DC, Smith BL, Younger JW, Garber JE, Duda RB, Mayzel KA, Isselbacher KJ, Friend SH, Haber D. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med. 1996 Jan 18; 334(3):143-9. PMID: 8531968.
        View in: PubMed
      220. Lamartine J, Nichols KE, Yin L, Krainer M, Heitzmann F, Bernard A, Gaudi S, Lenoir GM, Sullivan JL, Ikeda JE, Porta G, Schlessinger D, Romeo G, Haber D, Sylla BS, Harkin DP. Physical map and cosmid contig encompassing a new interstitial deletion of the X-linked lymphoproliferative syndrome region. Eur J Hum Genet. 1996; 4(6):342-51. PMID: 9043868.
        View in: PubMed
      221. Englert C, Vidal M, Maheswaran S, Ge Y, Ezzell RM, Isselbacher KJ, Haber D. Truncated WT1 mutants alter the subnuclear localization of the wild-type protein. Proc Natl Acad Sci U S A. 1995 Dec 19; 92(26):11960-4. PMID: 8618823; PMCID: PMC40275.
      222. Grundy P, Coppes MJ, Haber D. Molecular genetics of Wilms tumor. Hematol Oncol Clin North Am. 1995 Dec; 9(6):1201-15. PMID: 8591961.
        View in: PubMed
      223. Nichols KE, Re GG, Yan YX, Garvin AJ, Haber D. WT1 induces expression of insulin-like growth factor 2 in Wilms' tumor cells. Cancer Res. 1995 Oct 15; 55(20):4540-3. PMID: 7553624.
        View in: PubMed
      224. Englert C, Hou X, Maheswaran S, Bennett P, Ngwu C, Re GG, Garvin AJ, Rosner MR, Haber D. WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis. EMBO J. 1995 Oct 02; 14(19):4662-75. PMID: 7588596; PMCID: PMC394563.
      225. Maheswaran S, Englert C, Bennett P, Heinrich G, Haber D. The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. Genes Dev. 1995 Sep 01; 9(17):2143-56. PMID: 7657166.
        View in: PubMed
      226. Luo XN, Reddy JC, Yeyati PL, Idris AH, Hosono S, Haber D, Licht JD, Atweh GF. The tumor suppressor gene WT1 inhibits ras-mediated transformation. Oncogene. 1995 Aug 17; 11(4):743-50. PMID: 7651738.
        View in: PubMed
      227. Reddy JC, Morris JC, Wang J, English MA, Haber D, Shi Y, Licht JD. WT1-mediated transcriptional activation is inhibited by dominant negative mutant proteins. J Biol Chem. 1995 May 05; 270(18):10878-84. PMID: 7738027.
        View in: PubMed
      228. Haber D. Telomeres, cancer, and immortality. N Engl J Med. 1995 Apr 06; 332(14):955-6. PMID: 7877656.
        View in: PubMed
      229. Coppes MJ, Haber D, Grundy PE. Genetic events in the development of Wilms' tumor. N Engl J Med. 1994 Sep 01; 331(9):586-90. PMID: 8047084.
        View in: PubMed
      230. Weremowicz S, Kozakewich HP, Haber D, Park S, Morton CC, Fletcher JA. Identification of genetically aberrant cell lineages in Wilms' tumors. Genes Chromosomes Cancer. 1994 May; 10(1):40-8. PMID: 7519872.
        View in: PubMed
      231. Haber D, Park S, Maheswaran S, Englert C, Re GG, Hazen-Martin DJ, Sens DA, Garvin AJ. WT1-mediated growth suppression of Wilms tumor cells expressing a WT1 splicing variant. Science. 1993 Dec 24; 262(5142):2057-9. PMID: 8266105.
        View in: PubMed
      232. Park S, Bernard A, Bove KE, Sens DA, Hazen-Martin DJ, Garvin AJ, Haber D. Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour. Nat Genet. 1993 Dec; 5(4):363-7. PMID: 8298644.
        View in: PubMed
      233. Park S, Tomlinson G, Nisen P, Haber D. Altered trans-activational properties of a mutated WT1 gene product in a WAGR-associated Wilms' tumor. Cancer Res. 1993 Oct 15; 53(20):4757-60. PMID: 8402654.
        View in: PubMed
      234. Maheswaran S, Park S, Bernard A, Morris JF, Rauscher FJ, Hill DE, Haber D. Physical and functional interaction between WT1 and p53 proteins. Proc Natl Acad Sci U S A. 1993 Jun 01; 90(11):5100-4. PMID: 8389468; PMCID: PMC46662.
      235. Roberts DJ, Haber D, Sklar J, Crum CP. Extrarenal Wilms' tumors. A study of their relationship with classical renal Wilms' tumor using expression of WT1 as a molecular marker. Lab Invest. 1993 May; 68(5):528-36. PMID: 8388523.
        View in: PubMed
      236. Skare J, Wu BL, Madan S, Pulijaal V, Purtilo D, Haber D, Nelson D, Sylla B, Grierson H, Nitowsky H. Characterization of three overlapping deletions causing X-linked lymphoproliferative disease. Genomics. 1993 Apr; 16(1):254-5. PMID: 8387453.
        View in: PubMed
      237. Baird PN, Groves N, Haber D, Housman DE, Cowell JK. Identification of mutations in the WT1 gene in tumours from patients with the WAGR syndrome. Oncogene. 1992 Nov; 7(11):2141-9. PMID: 1331933.
        View in: PubMed
      238. Haber D, Timmers HT, Pelletier J, Sharp PA, Housman DE. A dominant mutation in the Wilms tumor gene WT1 cooperates with the viral oncogene E1A in transformation of primary kidney cells. Proc Natl Acad Sci U S A. 1992 Jul 01; 89(13):6010-4. PMID: 1321431; PMCID: PMC402128.
      239. Haber D, Buckler AJ. WT1: a novel tumor suppressor gene inactivated in Wilms' tumor. New Biol. 1992 Feb; 4(2):97-106. PMID: 1313285.
        View in: PubMed
      240. Haber D. Multidrug resistance (MDR 1) in leukemia: is it time to test? Blood. 1992 Jan 15; 79(2):295-8. PMID: 1346094.
        View in: PubMed
      241. Haber D, Housman DE. The genetics of Wilms' tumor. Adv Cancer Res. 1992; 59:41-68. PMID: 1325734.
        View in: PubMed
      242. Haber D, Housman DE. Role of the WT1 gene in Wilms' tumour. Cancer Surv. 1992; 12:105-17. PMID: 1322241.
        View in: PubMed
      243. Haber D, Sohn RL, Buckler AJ, Pelletier J, Call KM, Housman DE. Alternative splicing and genomic structure of the Wilms tumor gene WT1. Proc Natl Acad Sci U S A. 1991 Nov 01; 88(21):9618-22. PMID: 1658787; PMCID: PMC52769.
      244. Grundy P, Telzerow P, Paterson MC, Haber D, Berman B, Li F, Garber J. Chromosome 11 uniparental isodisomy predisposing to embryonal neoplasms. Lancet. 1991 Oct 26; 338(8774):1079-80. PMID: 1681381.
        View in: PubMed
      245. Pelletier J, Bruening W, Li FP, Haber D, Glaser T, Housman DE. WT1 mutations contribute to abnormal genital system development and hereditary Wilms' tumour. Nature. 1991 Oct 03; 353(6343):431-4. PMID: 1654525.
        View in: PubMed
      246. Schwartz CE, Haber D, Stanton VP, Strong LC, Skolnick MH, Housman DE. Familial predisposition to Wilms tumor does not segregate with the WT1 gene. Genomics. 1991 Aug; 10(4):927-30. PMID: 1655633.
        View in: PubMed
      247. Pelletier J, Schalling M, Buckler AJ, Rogers A, Haber D, Housman D. Expression of the Wilms' tumor gene WT1 in the murine urogenital system. Genes Dev. 1991 Aug; 5(8):1345-56. PMID: 1651275.
        View in: PubMed
      248. Huff V, Miwa H, Haber D, Call KM, Housman D, Strong LC, Saunders GF. Evidence for WT1 as a Wilms tumor (WT) gene: intragenic germinal deletion in bilateral WT. Am J Hum Genet. 1991 May; 48(5):997-1003. PMID: 1673293; PMCID: PMC1683037.
      249. Buckler AJ, Chang DD, Graw SL, Brook JD, Haber D, Sharp PA, Housman DE. Exon amplification: a strategy to isolate mammalian genes based on RNA splicing. Proc Natl Acad Sci U S A. 1991 May 01; 88(9):4005-9. PMID: 1850845; PMCID: PMC51582.
      250. Cowell JK, Wadey RB, Haber D, Call KM, Housman DE, Pritchard J. Structural rearrangements of the WT1 gene in Wilms' tumour cells. Oncogene. 1991 Apr; 6(4):595-9. PMID: 1851548.
        View in: PubMed
      251. Buckler AJ, Pelletier J, Haber D, Glaser T, Housman DE. Isolation, characterization, and expression of the murine Wilms' tumor gene (WT1) during kidney development. Mol Cell Biol. 1991 Mar; 11(3):1707-12. PMID: 1671709; PMCID: PMC369476.
      252. Haber D, Housman DE. Rate-limiting steps: the genetics of pediatric cancers. Cell. 1991 Jan 11; 64(1):5-8. PMID: 1846091.
        View in: PubMed
      253. Haber D, Buckler AJ, Glaser T, Call KM, Pelletier J, Sohn RL, Douglass EC, Housman DE. An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor. Cell. 1990 Jun 29; 61(7):1257-69. PMID: 2163761.
        View in: PubMed
      254. Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber D, Rose EA, Kral A, Yeger H, Lewis WH. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell. 1990 Feb 09; 60(3):509-20. PMID: 2154335.
        View in: PubMed
      255. Haber D, Housman DE. MspI/HpaII polymorphism in the human multidrug resistance gene 1. Nucleic Acids Res. 1989 Dec 11; 17(23):10142. PMID: 2481261; PMCID: PMC335277.
      256. Croop JM, Raymond M, Haber D, Devault A, Arceci RJ, Gros P, Housman DE. The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol. 1989 Mar; 9(3):1346-50. PMID: 2471060; PMCID: PMC362730.
      257. Darzynkiewicz E, Stepinski J, Ekiel I, Jin Y, Haber D, Sijuwade T, Tahara SM. Beta-globin mRNAs capped with m7G, m2.7(2)G or m2.2.7(3)G differ in intrinsic translation efficiency. Nucleic Acids Res. 1988 Sep 26; 16(18):8953-62. PMID: 3174438; PMCID: PMC338645.
      258. Haber D, Mayer RJ. Primary gastrointestinal lymphoma. Semin Oncol. 1988 Apr; 15(2):154-69. PMID: 3285479.
        View in: PubMed
      259. Haber D, Schimke RT. Unstable amplification of an altered dihydrofolate reductase gene associated with double-minute chromosomes. Cell. 1981 Nov; 26(3 Pt 1):355-62. PMID: 7326744.
        View in: PubMed
      260. Haber D, Fox DA, Dynan WS, Thilly WG. Cell density dependence of focus formation in the C3H/10T1/2 transformation assay. Cancer Res. 1977 Jun; 37(6):1644-8. PMID: 558052.
        View in: PubMed